<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/cc2167.anc" start="27143" end="27150" sStart="26989" offset="154" sid="r10.wait.v.0843" wn="2" wnkey="wait%2:42:01::" annotator="cgozo" text="Additionally, approved product labels recommend stopping the drotrecogin alfa (activated) infusion 2 hours before invasive procedures and waiting 12 hours after major surgical procedures to restart the infusion after ensuring adequate hemostasis [ 6 ] . The infusion may be restarted immediately after uncomplicated, less invasive procedures after ensuring adequate hemostasis." />
    <s path="[OANC]/data/written_2/technical/biomed/cc2167.anc" start="29386" end="29392" sStart="null" offset="90" sid="null" wn="6" wnkey="severe%5:00:01:bad:00" annotator="vebatchelder" text="Patients that appear to be at risk for such a complication are those with severe coagulopathy (i.e." />
    <s path="[OANC]/data/written_2/technical/biomed/cc2167.anc" start="31605" end="31611" sStart="null" offset="72" sid="r11.severe.j.0517" wn="1" wnkey="severe%5:00:00:intense:00" annotator="vebatchelder" text="Drotrecogin alfa (activated) significantly reduces mortality in severe sepsis." />
    <s path="[OANC]/data/written_2/technical/biomed/cc2167.anc" start="28515" end="28521" sStart="null" offset="179" sid="r11.severe.j.0514" wn="1" wnkey="severe%5:00:00:intense:00" annotator="vebatchelder" text="However, all patients experiencing ICH had a diagnosis of severe sepsis and a platelet count of 30,000/mm 3or less, suggesting that the event rate for the severe sepsis population overall may exceed 0.4% [ 12 ] . In a recently completed phase 2 trial of platelet activating factor-ase, an ICH event rate of 2.3% (1/43) was reported in placebo-treated sepsis patients (Opal S, personal communication)." />
    <s path="[OANC]/data/written_2/technical/biomed/cc2167.anc" start="25690" end="25696" sStart="null" offset="118" sid="r11.severe.j.0511" wn="1" wnkey="severe%5:00:00:intense:00" annotator="vebatchelder" text="Indeed, serious bleeding events in drotrecogin alfa (activated) patients appear to be associated with severe thrombocytopenia, suggesting that this characteristic may be a risk factor for bleeding complications." />
    <s path="[OANC]/data/written_2/technical/biomed/cc2167.anc" start="24169" end="24175" sStart="null" offset="223" sid="r11.severe.j.0508" wn="1" wnkey="severe%5:00:00:intense:00" annotator="vebatchelder" text="Serious bleeding event rates for both active treatment and placebo patients enrolled in clinical trials of drotrecogin alfa (activated) probably underestimate the bleeding risk for all patients with severe sepsis." />
  </sentences>
</list>